Blueprint Medicines Corp Stock Forecast:
Based on the analysis of 14 analysts, the average target price for Blueprint Medicines Corp over the next 12 months is USD 62.47, and the average analyst rating is Buy. However, Stock Target Advisor’s own analysis indicates a bearish outlook based on 2 positive signals and 6 negative signals. The stock’s last closing price was USD 56.25. Over the past week, the stock price has increased by +2.01%, over the past month by +14.68%, and over the last year, it has decreased by -1.95%.
Analysts Coverage Change:
- Needham & Company maintains a “Buy” rating for Blueprint Medicines Corp. and raises the target price to $67 from $65.
- Wells Fargo & Company maintains an “Equal-Weight” rating for Blueprint Medicines Corp. and raises the target price to $48 from $47.
- Barclays maintains an “Equal-Weight” rating for Blueprint Medicines Corp. and raises the target price to $46 from $44.
- Wedbush Securities reiterates an “Outperform” rating for Blueprint Medicines Corp. and maintains the target price at $75.
- H.C. Wainwright maintains a “Buy” rating for Blueprint Medicines Corp. and raises the target price to $85 from $75.
About Blueprint Medicines Corp.:
Blueprint Medicines Corporation is a precision therapy company that focuses on developing targeted treatments for specific genetic mutations found in various types of cancers and blood disorders. The company’s primary goal is to create therapies that are tailored to patients with genomically defined conditions.
One of Blueprint Medicines’ key drug candidates is AYVAKIT, which is being developed for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also working on BLU-263, an orally available inhibitor of the KIT protein, intended for the treatment of indolent SM and other mast cell disorders. Another drug in their pipeline is Fisogatinib, which has potential applications in several solid tumors.
In addition to these, Blueprint Medicines is developing GAVRETO, a targeted therapy for RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors. They are also working on BLU-701 and BLU-945, which target epidermal growth factor receptor (EGFR) driven non-small-cell lung carcinoma (NSCLC). Furthermore, they have BLU-451 in development for NSCLC patients with EGFR gene exon 20 insertion mutations. These drug candidates aim to address specific genetic alterations commonly found in these cancers.
Blueprint Medicines also has ongoing research programs for other conditions. BLU-782 is being developed for the treatment of fibrodysplasia ossificans progressive, a rare disorder characterized by abnormal bone formation. BLU-222 targets cyclin E aberrant cancers, and BLU-852 is focused on advanced cancers.
The company has established collaboration and license agreements with various organizations, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, Hoffmann-La Roche, and Zai Lab. These partnerships enable Blueprint Medicines to leverage expertise and resources to advance their drug development programs.
Blueprint Medicines Corporation, originally known as Hoyle Pharmaceuticals, Inc., was incorporated in 2008 and changed its name to Blueprint Medicines Corporation in June 2011. The company is headquartered in Cambridge, Massachusetts, but operates globally, with a focus on both the United States and international markets.
